A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases
By recognizing a different epitope, similarly potent neutralization of TSLP activities, and longer circulating half-life than tezepelumab, novel anti-TSLP antibody TAVO101 offers a potential best-in class therapeutics for various TSLP-mediated diseases.
Authors
- Ying Jin (ORCID: https://orcid.org/0000-0003-0840-773X)
- Guangmao Mu
- Mark L. Chiu (ORCID: https://orcid.org/0000-0001-6300-404X)
- Susan H. Tam (ORCID: https://orcid.org/0000-0002-4941-8235)
- Minseon Cho
- Chao Han (ORCID: https://orcid.org/0000-0002-0823-9329)
- Mark Tornetta (ORCID: https://orcid.org/0009-0002-5997-0426)
- Peng Chen (ORCID: https://orcid.org/0000-0002-1536-4945)
- Di Zhang (ORCID: https://orcid.org/0000-0001-5008-372X)
- Mingcan Yu (ORCID: https://orcid.org/0009-0001-4221-0829)
- Lihua Shi (ORCID: https://orcid.org/0000-0001-8629-0931)
- Man‐Cheong Fung
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3389/fimmu.2024.1442588
- Citations
- 8
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.61